Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-Current Assets: 2017-2024

Historic Non-Current Assets for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $12.6 million.

  • Protagonist Therapeutics' Non-Current Assets fell 9.30% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.3 million, marking a year-over-year decrease of 9.30%. This contributed to the annual value of $12.6 million for FY2024, which is 486.64% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Non-Current Assets of $12.6 million as of FY2024, which was up 486.64% from $2.1 million recorded in FY2023.
  • Protagonist Therapeutics' Non-Current Assets' 5-year high stood at $12.6 million during FY2024, with a 5-year trough of $2.1 million in FY2023.
  • Over the past 3 years, Protagonist Therapeutics' median Non-Current Assets value was $4.6 million (recorded in 2022), while the average stood at $6.5 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first slumped by 53.55% in 2023, then soared by 486.64% in 2024.
  • Yearly analysis of 5 years shows Protagonist Therapeutics' Non-Current Assets stood at $8.9 million in 2020, then decreased by 21.47% to $7.0 million in 2021, then crashed by 33.52% to $4.6 million in 2022, then plummeted by 53.55% to $2.1 million in 2023, then spiked by 486.64% to $12.6 million in 2024.